市場調查報告書
商品編碼
1533040
到 2030 年亞太地區填充飾面製造市場預測 - 區域分析 - 按產品、模式和最終用戶Asia Pacific Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product, Modality, and End User |
2022年,亞太地區填充飾面製造市場價值為18.6735億美元,預計2030年將達到42.0236億美元;預計2022年至2030年複合年成長率為10.7%。
新興市場的低商業成本推動亞太填充飾面製造市場
許多亞洲國家正在成為全球各種生物製藥製造商有吸引力的外包地點。中國、印度和亞洲其他國家的低製造和營運成本是推動合約製造的關鍵因素。此外,中國和印度生物製藥行業的最新發展表明該市場潛力巨大。不斷成長的生物製劑和生物相似藥產品線進一步為亞太地區的合約製造商開闢了新的途徑。由於營運成本較低,合約製造主要有利於早期藥物創新者。為了滿足不斷成長的需求,許多 CMO 正在擴大其製造能力。例如,2020年1月,藥明康德旗下合全藥業有限公司在中國開設了一家新的大型寡核苷酸活性藥物成分(API)生產工廠。
亞太地區填充飾面製造市場概覽
在亞太地區,中國是填充飾面製造的最大市場。市場的成長主要歸因於中國填充劑製造流程的技術進步、市場參與者的不斷發展、生物製藥行業的擴張以及慢性病盛行率的不斷上升。中國有超過500家生物製品/生物製藥公司。大多數從事研發的機構是由海歸或西方/合資公司設立的。儘管估計差異很大,但分析師認為,中國政府每年透過資助計畫在生物技術研發上花費超過 6 億美元。中國國家和地方政府也投資投資IT企業的準創投公司。
市場參與者正在透過有機和無機成長策略擴大業務。例如,藥明生物在中國無錫開設藥品工廠,於 2022 年 6 月將預充式注射器 (PFS) 產能提高至 1,700 萬支/年。
由合約開發製造組織 (CDMO) 藥明生物營運的最新 DP 設施被稱為 DP5,它擁有先進的隔離器填充線,可提供可靠、連續的填充服務。據該公司稱,這為 PFS 提供了多種體積輸送選項,包括 1.25 mL、3 mL、1 mL 和 1 mL。
亞太地區填充飾面製造市場收入及 2030 年預測(百萬美元)
亞太地區填充飾面製造市場細分
亞太地區填充表面製造市場根據產品、模式、最終用戶和國家進行細分。根據產品,亞太地區灌裝製造市場分為消耗品和儀器。到2022年,消耗品細分市場將佔據更大的市場佔有率。
就形式而言,亞太地區填充加工製造市場分為重組蛋白、單株抗體、疫苗、細胞療法和生物療法、基因療法等。 2022 年,疫苗領域佔據最大的市場。
依最終用戶分類,亞太地區填充劑製造市場分為合約製造組織、生物製藥公司等。 2022 年,合約製造組織細分市場佔據最大的市場佔有率。
按國家/地區分類,亞太地區填充飾面製造市場分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。 2022 年,中國將主導亞太地區填充塗料製造市場佔有率。
Becton Dickinson and Co、Gerresheimer AG、IMA Industria Macchine Automatiche SpA、Maquinaria Industrial Dara SL、Nipro Medical Asia Pacific NV、NNE AS、Optima Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Group SpA、Synte Technology GmbticalH 和 West Services Inc 是亞太地區填充飾面製造市場的一些領導者。
The Asia Pacific fill finish manufacturing market was valued at US$ 1,867.35 million in 2022 and is expected to reach US$ 4,202.36 million by 2030; it is estimated to grow at a CAGR of 10.7% from 2022 to 2030.
Low Business Costs in Emerging Markets Boosts Asia Pacific Fill Finish Manufacturing Market
Many Asian countries are emerging as attractive outsourcing locations for various biopharmaceutical manufacturers across the globe. Low manufacturing and operating costs in China, India, and other countries in Asia are the key factors boosting contract manufacturing. Moreover, recent developments in the biopharmaceutical industry in China and India indicate significant potential for the market. The growing pipelines of biologics and biosimilars are further opening new avenues for the contract manufacturers in APAC. Contract manufacturing mostly benefits early-stage drug innovators owing to lower operational costs. To meet the growing demand, many CMOs are expanding their manufacturing capabilities. For instance, in January 2020, STA Pharmaceutical Co., Ltd-a WuXi AppTec company-opened a new large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in China.
Asia Pacific Fill Finish Manufacturing Market Overview
In Asia Pacific, China is the largest market for fill finish manufacturing. The growth of the market is primarily attributed to the rising technological advancements in fill finish manufacturing processes in China, increasing developments by the market players, the biopharmaceutical industry's expansion, and the growing prevalence of chronic diseases. There are more than 500 biological product/biopharmaceutical companies in China. Most of those involved in R&D were established by returnees from abroad or by Western/joint venture companies. Although estimates vary widely, analysts believe that the Chinese government spends more than US$ 600 million annually on biotech R&D through its funding initiatives. China's national and local governments also invest in quasi-venture capital companies that invest in IT enterprises.
The market players are expanding their business through organic and inorganic growth strategies. For instance, WuXi Biologics increased the capacity of prefilled syringes (PFS) to 17 million units yearly in June 2022 by opening its drug product factory in Wuxi, China.
The most recent D.P. facility operated by WuXi Bio, a contract development manufacturing organization (CDMO), is called DP5, and it has an advanced isolator filling line for reliable, continuous filling services. According to the company, this provides PFS with a variety of volume delivery options, including 1.25 mL, 3 mL, 1 mL, and 1 mL.
Asia Pacific Fill Finish Manufacturing Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Fill Finish Manufacturing Market Segmentation
The Asia Pacific fill finish manufacturing market is segmented based on product, modality, end user, and country. Based on product, the Asia Pacific fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held a larger market share in 2022. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.
In terms of modality, the Asia Pacific fill finish manufacturing market is segmented into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held the largest market share in 2022.
By end user, the Asia Pacific fill finish manufacturing market is categorized into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held the largest market share in 2022.
Based on country, the Asia Pacific fill finish manufacturing market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific fill finish manufacturing market share in 2022.
Becton Dickinson and Co, Gerresheimer AG, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Asia Pacific NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc are some of the leading players operating in the Asia Pacific fill finish manufacturing market.